Cargando…

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma

Detalles Bibliográficos
Autores principales:	Bjørn, Jon, Donia, Marco V, Andersen, Rikke, Hadrup, Sine R, Svane, Inge Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991248/ http://dx.doi.org/10.1186/2051-1426-1-S1-P241

Ejemplares similares

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
por: Ellebaek, Eva, et al.
Publicado: (2012)

The antigen specific composition of melanoma tumor infiltrating lymphocytes?
por: Hadrup, Sine Reker
Publicado: (2012)

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients
por: Iversen, Trine Zeeberg, et al.
Publicado: (2013)

Characterization of Ex Vivo Expanded Tumor Infiltrating Lymphocytes from Patients with Malignant Melanoma for Clinical Application
por: Junker, Niels, et al.
Publicado: (2011)

S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
por: Svane, I, et al.
Publicado: (2014)

Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
por: Donia, Marco, et al.
Publicado: (2012)

Polyfunctional incompletely differentiated CD8+ T cells accumulates after adoptive transfer of tumor-infiltrating lymphocytes and establish immunological memory in patients with metastatic melanoma
por: Donia, Marco, et al.
Publicado: (2015)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Adoptive cell therapy with tumor infiltrating lymphocytes and intermediate dose IL-2 for metastatic melanoma
por: Andersen, Rikke, et al.
Publicado: (2014)

Neoantigen-reactive CD8(+) T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
por: Kristensen, Nikolaj Pagh, et al.
Publicado: (2022)

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
por: Hulen, Thomas Morgan, et al.
Publicado: (2023)

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab
por: Kverneland, Anders H., et al.
Publicado: (2018)

“Immunotherapy of cancer: present status and future promise”: Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd–25th September 2013
por: Donia, Marco, et al.
Publicado: (2014)

Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
por: Hansen, Ulla Kring, et al.
Publicado: (2020)

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
por: Mullinax, John E., et al.
Publicado: (2018)

Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
por: Borch, Troels Holz, et al.
Publicado: (2020)

Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program
por: Rapoport, Bernardo L., et al.
Publicado: (2016)

A pilot study of Ipilimumab in patients with stage IV melanoma receiving palliative radiation therapy
por: Knox, Susan, et al.
Publicado: (2014)

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8(+) T Cells in Non-Melanoma Cancers Compared to Melanoma
por: Gokuldass, Aishwarya, et al.
Publicado: (2020)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

High frequency of T cells specific for cryptic epitopes in melanoma patients
por: Andersen, Rikke Sick, et al.
Publicado: (2013)

Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program
por: Berrocal, Alfonso, et al.
Publicado: (2014)

Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
por: Hadrup, Sine, et al.
Publicado: (2012)

BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
por: Donia, Marco, et al.
Publicado: (2012)

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
por: Revicki, Dennis A, et al.
Publicado: (2012)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
por: Chiarion-Sileni, V, et al.
Publicado: (2014)

Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy
por: Chamberlain, Christopher Aled, et al.
Publicado: (2022)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
por: Verschraegen, Claire
Publicado: (2012)

Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
por: Sherrill, B, et al.
Publicado: (2013)

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas
por: Cordova, Adriana, et al.
Publicado: (2012)

Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma
por: Li, Wei, et al.
Publicado: (2017)

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
por: Lebbé, Celeste, et al.
Publicado: (2019)

Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes
por: Håkansson, A, et al.
Publicado: (2001)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab-Induced Neutropenia in Melanoma
por: Ban-Hoefen, Makiko, et al.
Publicado: (2016)

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
por: Jamal, Rahima, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dbqaf56n9kcf6pjjtveaefafla